(Q39229046)

10 September 2017

title

Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist (English)

1 reference

10 September 2017

Michel A Steiner

1

1 reference

10 September 2017

John Gatfield

2

1 reference

10 September 2017

Catherine Brisbare-Roch

3

1 reference

10 September 2017

Hendrik Dietrich

4

1 reference

10 September 2017

Alexander Treiber

5

1 reference

10 September 2017

Francois Jenck

6

1 reference

10 September 2017

Christoph Boss

7

1 reference

10 September 2017

language of work or name

1 reference

15 April 2013

1 reference

10 September 2017

1 reference

10 September 2017

volume

8

1 reference

10 September 2017

issue

6

1 reference

10 September 2017

page(s)

898-903

1 reference

Connectomics of orexin-producing neurons: interface of systems of emotion, energy homeostasis and arousal

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300003

Promotion of sleep by targeting the orexin system in rats, dogs and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300003

The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300003

Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300003

International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin receptor function, nomenclature and pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300003

1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300003

Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300003

Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300003

Hypocretin/orexin contributes to the expression of some but not all forms of stress and arousal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300003

The brain orexin system and almorexant in fear-conditioned startle reactions in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300003

Orexin-1 receptor antagonism fails to reduce anxiety-like behaviour in either plus-maze-naïve or plus-maze-experienced mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300003

Differential effects of the dual orexin receptor antagonist almorexant and the GABA(A)-α1 receptor modulator zolpidem, alone or combined with ethanol, on motor performance in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300003

Intact learning and memory in rats following treatment with the dual orexin receptor antagonist almorexant

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300003

21 January 2018

Identifiers

DOI

10.1002/CMDC.201300003

1 reference

10 September 2017

1 reference